Biotechnology Animations – Biotechnology Illustrations

Immutep Announces Positive Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
Immutep S.A. announced today interim results from its ongoing Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 was administered the day after weekly paclitaxel for six months. The interim results show a clinical response rate of 50 per cent compared to 25 per cent with paclitaxel alone. In addition, a robust immune response was observed in clinically-responding patients.

Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting
A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux® (cetuximab) to standard oxaliplatin-based chemotherapy (FOLFOX-4) in previously untreated metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors results in significantly higher efficacy than chemotherapy alone.

Antioxidants Offer Pain Relief In Patients With Chronic Pancreatitis
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage).

Factors Other Than Central Sleep Apnea May Contribute To Poor Sleep Quality In Heart-Failure Patients
A study in the Jan. 1 issue of the journal Sleep demonstrates that the frequent arousals from sleep that occur in heart failure patients with central sleep apnea (CSA) may reflect the presence of another underlying arousal disorder rather than being a defensive mechanism to terminate apneas.

Study Shows Machine Perfusion Significantly Improves Transplant Results
A landmark study published in the New England Journal of Medicine (NEJM) demonstrates that use of a specially-designed machine to store kidneys for transplantation offers significant benefits in kidney survival and function when compared to those stored in a traditional "ice box", or cold storage.

Novartis Strengthens Vaccine Pipeline With Agreement For Novel CMV Vaccines Candidate
Novartis has strengthened its vaccines pipeline through an exclusive agreement to license AlphaVax' investigational Cytomegalovirus (CMV) vaccine program. This CMV agreement adds to Novartis' promising early stage pipeline of novel vaccines, which focuses on significant unmet needs for the prevention of fatal diseases such as meningococcal infections and other hospital and community acquired infections.

Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel.

Andromeda Biotech Announces Successful Phase III Interim Results Of Its Lead Product, DiaPep277 For Type 1 Diabetes
Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (CBI), focused on the development of innovative treatment for autoimmune diabetes announces positive results following the Phase III interim analysis for the company's lead product, DiaPep277 for the treatment of Type 1 diabetes.

Preventive Antibiotic Use Reduced ICU Deaths
Researchers studying nearly 6,000 patients in intensive care units (ICUs) in 13 hospitals throughout the Netherlands, found that giving antibiotics as a preventive measure to ICU patients increased their chances of survival. The study was the work of first author Dr.

Prevention Of Organ Rejection In Stable Kidney Transplant Patients - LCP-Tacroâ„¢ Moves Into Clinical Phase 3
LifeCycle Pharma A/S (OMX:LCP) today announced the enrollment of the first patient in it's Phase 3 clinical trial program for use of LCP-Tacroâ„¢ in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the program. The study will be conducted at approximately 50 sites in U.S.

Phase IIa Clinical Trial Results Relating To CK-1827452 In Patients With Ischemic Cardiomyopathy And Angina
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today top-line results from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.  The primary safety endpoint was defined as stopping an exercise test during treatment with CK-1827452 (versus placebo) due to unacceptable angina at an earlier exercise stage than at baseline.

Genetic Variation In Young Heart Attack Patients Results In Anticlotting Drug Clopidogrel Being Less Effective
If a young heart attack patient (under 45 years of age) has a certain genetic variation, the anticlotting drug clopidogrel is less effective in that person and they are much more likely to die, have another heart attack, require urgent repeat coronary intervention or have stent thrombosis.

Innovative Gene Therapy Approach To Prevent Amputations In Patients Suffering Severe Peripheral Artery Disease
Cardiologists at Rush University Medical Center are studying an investigational medication to prevent amputations in patients suffering the most severe form of peripheral arterial disease. The study involves use of a highly innovative gene therapy approach to promote new blood vessel growth in the legs of patients with critical limb ischemia.

Pegloticase BLA Filing Accepted For Priority Review By FDA
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted the Company's BLA with a priority review status which accelerates the review period to six months.

SciClone Announces First Patient Enrolled In Phase 2 Clinical Trial Using SCV-07 To Prevent Oral Mucositis
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient in its phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of SCV-07 for prevention of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer.